XenoPort Inc
(NASDAQ: XNPT)
| Exchange: | NASDAQ |
| Stock: | XenoPort, Inc. |
| Industry: | Biotechnology |
| Employees: | 88 |
| XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders. The product candidates are prodrugs that are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. The Company focuses its development and commercialization efforts on treatments of diseases with unmet medical needs, with an emphasis on central nervous system disorders. The products are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. In April 2011, the United States Food and Drug Administration (FDA), approved the Company’s first product, known in the United States as Horizant (gabapentin enacarbil) Extended-Release Tablets, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults. |
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Japanese stock price data provided by Nomura Research Institute Ltd.; quotes delayed 20 minutes. Canadian fund data provided by CANNEX Financial Exchanges Ltd.
